Renal Substudies of EPO-TBI and POLAR

haemofilter

The EPO-TBI and POLAR trials present a unique opportunity to investigate the effect of potentially renoprotective therapies (EPO and hypothermia) on kidney function in TBI patients, and the ability of several novel biomarkers, including NGAL and cystatin C to detect kidney injury and response to treatment.

1 Moore EM, Bellomo R, Nichol AD, et al. The incidence of acute kidney injury in patients with traumatic brain injury. Ren Fail 2010; 32

2 Bagshaw SM, George C, Gibney RT, et al. A multi-center evaluation of early acute kidney injury in critically ill trauma patients. Ren Fail 2008; 30:581-589

3 Bagshaw SM, George C, Dinu I, et al. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrology Dialysis Transplantation 2008; 23:1203-1210

4 Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843
Study Progress: Recruitment for the EPO-TBI trial commenced in May 2010 and is now complete; recruitment for the POLAR trial is over halfway to completion. Results for the Renal substudy of EPO-TBI will be published after those of the EPO-TBI trial late in 2015.
Collaboration:
The Renal Substudies of EPO-TBI and POLAR will be conducted in collaboration with the ANZICS Clinical Trials Group (ANZICS-CTG) EPO-TBI and POLAR Investigators.
Approval:
The Renal Substudies of EPO-TBI and POLAR have been endorsed by the ANZICS Clinical Trials Group (CTG) and approved by the ANZIC Research Centre Board and the EPO-TBI and POLAR Management Committees.Contact: For further information about this project, please contact Elizabeth Moore at the ANZIC-RC by email.